Joseph Pierre Aboumsallem: ET Treatment Enters a New Chapter
Joseph Pierre Aboumsallem, Drug Development Lead – siRNA Therapeutics, Postdoctoral Researcher, Project Manager at Erasmus MC, Project Manager at University Medical Center Groningen (UMCG), shared a post on LinkedIn about a recent article by Isabelle Plo and William Vainchenker, published in NEJM, adding:
“Amazing news!!
The FDA has approved ropeginterferon alfa-2b for essential thrombocythemia (ET), the first new treatment approval for the disease in nearly 30 years.
ET is a chronic myeloproliferative neoplasm driven by clonal haematopoiesis.
Persistent thrombocytosis increases the risk of thrombosis and bleeding, and treatment options remain limited for patients who do not respond to or cannot tolerate hydroxyurea.
In SURPASS-ET, 37.4% of patients treated with ropeginterferon achieved a durable composite response, including blood count control, no progression of splenomegaly, and no thrombotic or haemorrhagic events, sustained at 9 and 12 months. The corresponding rate with anagrelide was 3.6%.
The molecular responses across JAK2, CALR and MPL are also important. Controlling platelet counts is one part of treatment.
Reducing the burden of the underlying clone is a different proposition and has been a long-standing goal in MPN research.
It is good to see interferon biology, developed over decades, now translating into a new treatment option for patients with ET.”
Title: Myeloproliferative Neoplasms
Authors: Isabelle Plo, William Vainchenker
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week